PT1297851E - Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca - Google Patents

Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca

Info

Publication number
PT1297851E
PT1297851E PT02021676T PT02021676T PT1297851E PT 1297851 E PT1297851 E PT 1297851E PT 02021676 T PT02021676 T PT 02021676T PT 02021676 T PT02021676 T PT 02021676T PT 1297851 E PT1297851 E PT 1297851E
Authority
PT
Portugal
Prior art keywords
cardiac hypertrophy
desacetilase
histone
inhibition
treatment
Prior art date
Application number
PT02021676T
Other languages
English (en)
Portuguese (pt)
Inventor
Michael R Bristow
Long Carlin
Timothy A Mckinsey
Eric N Olson
Original Assignee
Univ Texas
Univ Colorado A Body
Ate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Univ Colorado A Body, Ate filed Critical Univ Texas
Publication of PT1297851E publication Critical patent/PT1297851E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT02021676T 2001-09-27 2002-09-27 Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca PT1297851E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32531101P 2001-09-27 2001-09-27
US33404101P 2001-10-31 2001-10-31

Publications (1)

Publication Number Publication Date
PT1297851E true PT1297851E (pt) 2005-06-30

Family

ID=26984878

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02021676T PT1297851E (pt) 2001-09-27 2002-09-27 Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca

Country Status (8)

Country Link
US (4) US6706686B2 (enExample)
EP (1) EP1297851B1 (enExample)
JP (2) JP2003238445A (enExample)
AT (1) ATE287731T1 (enExample)
DE (1) DE60202727T2 (enExample)
DK (1) DK1297851T3 (enExample)
ES (1) ES2236415T3 (enExample)
PT (1) PT1297851E (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372957B1 (en) * 1998-11-10 2002-04-16 Board Of Regents, The University Of Texas System Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0410787A (pt) * 2003-05-21 2006-06-20 Univ Texas inibição da proteìna cinase c-mu (pkd) como um tratamento para hipertrofia cardìaca e insuficiência cardìaca
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
CA2555632A1 (en) * 2004-02-02 2005-08-18 Myogen, Inc. Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US20050288215A1 (en) * 2004-04-05 2005-12-29 Mckinsey Timothy A Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
EP1740945B1 (en) 2004-04-07 2018-09-19 Ncardia AG Non-invasive, in vitro functional tissue assay systems
DK1745144T3 (da) 2004-05-11 2011-02-07 Axiogenesis Ag Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7732475B2 (en) * 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007011757A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
MX2008001964A (es) * 2005-08-10 2008-03-26 Novartis Ag Metodo de uso de inhibidores de desacetilasa.
WO2007059533A2 (en) * 2005-11-18 2007-05-24 Myogen, Inc. Uses for camki i and hdacs in the treatment of heart conditions
AU2006318652A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the HDAC inhibitor FK228
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007126958A2 (en) * 2006-03-29 2007-11-08 Edward Via Virginia College Of Osteopathic Medicine Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
CA2641951A1 (en) * 2006-04-06 2007-10-11 Novartis Ag Combination of organic compounds
WO2007120839A2 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
BRPI0720991A8 (pt) * 2006-12-29 2016-03-15 Gloucester Pharmaceuticals Inc Preparação da romidepsina
AU2007342030B2 (en) * 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
US9884031B2 (en) * 2007-05-09 2018-02-06 The Trustees Of The University Of Pennsylvania Use of HDAC inhibitors for treatment of cardiac rhythm disorders
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
US9226965B2 (en) * 2007-10-05 2016-01-05 U.S. Department Of Veterans Affairs Method and composition for treating heart failure
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
US20100212036A1 (en) * 2008-09-30 2010-08-19 Olson Eric N Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
SG187032A1 (en) 2010-07-12 2013-02-28 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
JP6025732B2 (ja) 2010-10-13 2016-11-16 テトラロジック シェイプ ユーケイ エルティーディー ヒストンデアセチラーゼ阻害薬のための医薬製剤
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3156303A1 (en) * 2019-10-03 2021-04-08 Tenaya Therapeutics, Inc. 5-fluoronicotinamide derivatives and uses thereof
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CN116942822A (zh) * 2023-06-12 2023-10-27 深圳大学 Hdac2在治疗室性心律失常中的应用
CN118766882B (zh) * 2024-09-12 2025-02-21 北京大学第三医院（北京大学第三临床医学院） 用于治疗心血管疾病的制剂及其应用和制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5968981A (en) * 1995-07-28 1999-10-19 The Regents Of The University Of California Retinoid suppression of ventricular muscle cell hypertrophy
JP2002528391A (ja) 1998-10-19 2002-09-03 メチルジェン，インク． 組合せ治療による遺伝子発現の修飾
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
EP1173562A2 (en) 1999-05-03 2002-01-23 Methylgene, Inc. Inhibition of histone deacetylase
WO2001014581A2 (en) 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017514A1 (en) * 1999-09-03 2001-03-15 The Salk Institute For Biological Studies Modulation of gene expression by modulating histone acetylation
EP1235618A2 (en) 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
JP2003518923A (ja) 1999-09-08 2003-06-17 スローン−ケターリング インスティチュート フォー キャンサー リサーチ デアセチラーゼ及びその阻害剤の結晶構造
KR101026205B1 (ko) 1999-11-23 2011-03-31 메틸진 인코포레이티드 히스톤 디아세틸라제의 억제제
CA2393725A1 (en) 1999-12-08 2001-06-14 Axys Pharmaceuticals, Inc. Histone deacetylase-8 proteins, nucleic acids, and methods of use
EP1438404A2 (en) 2000-03-24 2004-07-21 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
AU2002237240A1 (en) 2000-12-20 2002-07-01 Novartis Ag Histone deacetylase-related gene and protein
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

Also Published As

Publication number Publication date
US6946441B2 (en) 2005-09-20
US6706686B2 (en) 2004-03-16
JP2010001311A (ja) 2010-01-07
US20040186049A1 (en) 2004-09-23
JP2003238445A (ja) 2003-08-27
US20060025333A1 (en) 2006-02-02
ES2236415T3 (es) 2005-07-16
DK1297851T3 (da) 2005-05-30
US20060069014A1 (en) 2006-03-30
EP1297851B1 (en) 2005-01-26
DE60202727D1 (de) 2005-03-03
EP1297851A1 (en) 2003-04-02
DE60202727T2 (de) 2005-12-29
ATE287731T1 (de) 2005-02-15
US20030144340A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
PT1297851E (pt) Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca
EP1551812A4 (en) MITOTIC KINESINE HEMMER
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
ATE447577T1 (de) Mitotische kinesin-hemmer
EP1515724A4 (en) MITOTIC KINESINE HEMMER
ATE448207T1 (de) Mitotische kinesin-hemmer
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
UY27224A1 (es) Inhibidores de la rho-quinasa
DE60318177D1 (de) Rho-kinase inhibitoren
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA201100874A1 (ru) Соединения для лечения рака
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
WO2005065183A3 (en) Mitotic kinesin inhibitors
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
MY141048A (en) Morpholine derivatives as norepinephrine reuptake inhibitors
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus